Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Prevalence of Multidrug Resistance Tuberculosis

Version 1 : Received: 11 November 2020 / Approved: 12 November 2020 / Online: 12 November 2020 (08:24:40 CET)

How to cite: Bachani, P.; Kumar, L.; Kumar, N.; Shaukat, F. Prevalence of Multidrug Resistance Tuberculosis. Preprints 2020, 2020110327 (doi: 10.20944/preprints202011.0327.v1). Bachani, P.; Kumar, L.; Kumar, N.; Shaukat, F. Prevalence of Multidrug Resistance Tuberculosis. Preprints 2020, 2020110327 (doi: 10.20944/preprints202011.0327.v1).

Abstract

Introduction Tuberculosis is common in Pakistan. Due to various factors including socioeconomic factors, compliance is poor to anti-tuberculosis drugs, leading to resistance. We aim to determine the prevalence of Multidrug resistance (MDR) tuberculosis in Pakistani population.Methods A prospective observational study was conducted from April 1, 2019, to December 31, 2019, in the Pulmonology department of a tertiary care hospital in Pakistan. Culture and sensitivity were assessed using a sputum sample or, in cases of an absent sputum sample, from Broncho alveolar lavage.ResultsApproximately 71.3% percent patients who had tuberculosis were found to be resistant to Isoniazid and around 48.6% did not respond to Rifampin. Multi-drug resistant was found in 29.4% participants.ConclusionMulti-drug resistance tuberculosis is very prevalent in Pakistan, which may increase burden on health care system and may lead to various complications of tuberculosis.

Subject Areas

Multi-drug resistance; Tuberculosis; Pakistan

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.